HYAMAB
Updated 24 days ago
- Age: 126 years
- ID: 48611801/20
building 1, Wison building, 699 Zhongke Road, Pudong New Area, Shanghai, China
HyaMab, based in the Pharmaceutical Valley of Zhangjiang Innovation Cluster, is committed to novel anti-cancer therapeutics including monoclonal antibodies (mAbs), allogenic NK cells, and CAR-engineered NK / T cells with best-in-class and/or first-in-class (BIC/FIC) potentials. Working closely with international leading research laboratories such as Intelligent Medicine, Shanghai Institute for Advanced Immunochemical Studies (SIAIS) / ShanghaiTech University, as well as industrial R&D partners, HyaMab has established a comprehensive pipeline covering from discovery leads with novel mode-of-action (MoA) (e.g. NKp46, NKG2D, MICA/B, CD16, etc.) to clinical-stage development candidates (e.g. 4-1BB, NKG2A, etc.)... HyaMab's strategy is to harness the power of innate immunity (especially NK cells) to combat and stop the proliferation and metastasis of cancer cells. The two focal areas of HyaMab R&D are to develop 1) antibody modulators and 2) engineered immune cells that enhance and sustain..